Yoav Binenbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoav Binenbaum has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
3 shared publications - Wei-Hung Jung
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
3 shared publications Azra Haseki
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
2 shared publicationsEmie Humann
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
2 shared publications- Gil Shamai
Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel
2 shared publications Joshua M. Price
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
2 shared publications
Latest Publications
- Open Access
Programmable antigen-presenting scaffolds expand rare tumor-antigen-specific T cells from peripheral blood
Adoptive cellular therapies can be effective against solid tumors but rely on the identification and expansion of rare tumor-reactive T cells (TRTs). Here, we utilize antigen-presenting cell-mimetic scaffolds (APC-ms), a modular biomaterial platform that presents defined peptide-HLA and co-stimulatory ligands on a fluid lipid bilayer to selectively recover rare antigen-specific T cells from peripheral blood. Independent variation of peptide-HLA, co-stimulatory ligands, and cytokine support defined a formulation that enriched MART-1-specific T cells to above 2% of CD8 + T cells in 35 of 50 HLA-A*02:01 + healthy donors from low or undetectable baseline frequencies. Compared with mo-DCs, APC-ms achieved greater fold expansion of MART-1-specific T cells with increased functional avidity and preservation of an early differentiation phenotype, and generated a higher number of MART-1-specific clonotypes. In five of eight patients with treatment-naïve melanoma, APC-ms could enrich MART-1-specific T cells to a median of 13.7% of CD8 + cells (range 0.30 – 57.2%) Moreover, APC-ms could expand T cells specific for an HLA-A*24:01-restricted personal neoantigen that were previously undetectable in peripheral blood of a patient with melanoma. These findings establish APC-ms as a tunable platform for the recovery of rare TRTs from peripheral blood, supporting its further development for therapeutic TCR discovery and personalized adoptive cell therapy.
Open AccessProgrammable antigen-presenting scaffolds expand rare tumor-antigen-specific T cells from peripheral blood
Adoptive cellular therapies can be effective against solid tumors but rely on the identification and expansion of rare tumor-reactive T cells (TRTs). Here, we utilize antigen-presenting cell-mimetic scaffolds (APC-ms), a modular biomaterial platform that presents defined peptide-HLA and co-stimulatory ligands on a fluid lipid bilayer to selectively recover rare antigen-specific T cells from peripheral blood. Independent variation of peptide-HLA, co-stimulatory ligands, and cytokine support defined a formulation that enriched MART-1-specific T cells to above 2% of CD8 + T cells in 35 of 50 HLA-A*02:01 + healthy donors from low or undetectable baseline frequencies. Compared with mo-DCs, APC-ms achieved greater fold expansion of MART-1-specific T cells with increased functional avidity and preservation of an early differentiation phenotype, and generated a higher number of MART-1-specific clonotypes. In five of eight patients with treatment-naïve melanoma, APC-ms could enrich MART-1-specific T cells to a median of 13.7% of CD8 + cells (range 0.30 – 57.2%) Moreover, APC-ms could expand T cells specific for an HLA-A*24:01-restricted personal neoantigen that were previously undetectable in peripheral blood of a patient with melanoma. These findings establish APC-ms as a tunable platform for the recovery of rare TRTs from peripheral blood, supporting its further development for therapeutic TCR discovery and personalized adoptive cell therapy.
- Open Access
- 5 May 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (32) , e23274
Matrix Viscoelasticity Regulates Dendritic Cell Migration and Immune Priming
The tumor microenvironment shapes immune surveillance through its mechanical properties, yet the role of matrix viscoelasticity remains unclear. Here, we used a tunable collagen system that models human tissue viscoelasticity to define how matrix relaxation directs dendritic cell (DC) behavior. Slow‐relaxing, elastic networks restrict actomyosin‐driven remodeling, limiting DC motility and reducing DC‐T cell encounters and activation. Blocking DC migration in fast‐relaxing matrices recapitulated key aspects of the impaired T cell priming seen in elastic networks, identifying migration as a mechanical checkpoint for immune activation. Prolonged confinement in elastic matrices induced a mechanomemory state, locking DCs into a state of reduced motility and altered chromatin accessibility. Studies using patient‐derived ependymoma samples confirmed these findings, establishing viscoelastic relaxation as a key physical regulator of immune priming. Together, this tunable viscoelastic platform provides a defined, human‐relevant model to dissect and model mechanical control of immunity for therapeutic design.
- 5 May 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (32) , e23274
Open AccessMatrix Viscoelasticity Regulates Dendritic Cell Migration and Immune Priming
The tumor microenvironment shapes immune surveillance through its mechanical properties, yet the role of matrix viscoelasticity remains unclear. Here, we used a tunable collagen system that models human tissue viscoelasticity to define how matrix relaxation directs dendritic cell (DC) behavior. Slow‐relaxing, elastic networks restrict actomyosin‐driven remodeling, limiting DC motility and reducing DC‐T cell encounters and activation. Blocking DC migration in fast‐relaxing matrices recapitulated key aspects of the impaired T cell priming seen in elastic networks, identifying migration as a mechanical checkpoint for immune activation. Prolonged confinement in elastic matrices induced a mechanomemory state, locking DCs into a state of reduced motility and altered chromatin accessibility. Studies using patient‐derived ependymoma samples confirmed these findings, establishing viscoelastic relaxation as a key physical regulator of immune priming. Together, this tunable viscoelastic platform provides a defined, human‐relevant model to dissect and model mechanical control of immunity for therapeutic design.
- Open Access
Feeder-free generation of functional dendritic cells from human pluripotent stem cells
The scarcity of primary conventional dendritic cells (cDCs) and the limited effectiveness of monocyte-derived dendritic cells (moDCs) have long hindered progress in human dendritic cell research and immunotherapy. We developed a feeder-free differentiation platform that generates CD1c + CD141 + hPSC-cDCs phenotypically aligned with CD141 + tissue-resident cDC2 subsets found in human tissues. We further optimized the differentiation process using a Design-of-Experiments framework to refine cytokine and serum conditions, enhancing differentiation efficiency while reducing cytokine demand. These hPSC-cDCs exhibit efficient antigen uptake, defined cytokine responses, and robust priming of antigen-specific CD8 + T cell proliferation and effector differentiation, outperforming moDCs in direct comparison. Together, this work establishes a robust, and generalizable platform for mechanistic studies and translational development of dendritic cell-based vaccines and standardized ex vivo T cell expansion.
Open AccessFeeder-free generation of functional dendritic cells from human pluripotent stem cells
The scarcity of primary conventional dendritic cells (cDCs) and the limited effectiveness of monocyte-derived dendritic cells (moDCs) have long hindered progress in human dendritic cell research and immunotherapy. We developed a feeder-free differentiation platform that generates CD1c + CD141 + hPSC-cDCs phenotypically aligned with CD141 + tissue-resident cDC2 subsets found in human tissues. We further optimized the differentiation process using a Design-of-Experiments framework to refine cytokine and serum conditions, enhancing differentiation efficiency while reducing cytokine demand. These hPSC-cDCs exhibit efficient antigen uptake, defined cytokine responses, and robust priming of antigen-specific CD8 + T cell proliferation and effector differentiation, outperforming moDCs in direct comparison. Together, this work establishes a robust, and generalizable platform for mechanistic studies and translational development of dendritic cell-based vaccines and standardized ex vivo T cell expansion.
- Open Access
Matrix viscoelasticity regulates dendritic cell migration and immune priming
The tumor microenvironment shapes immune surveillance through its mechanical properties, yet the role of matrix viscoelasticity remains unclear. Here, we used a collagen system with tunable viscoelasticity to define how matrix relaxation directs dendritic cell (DC) behavior. Elastic matrices impaired DC migration by limiting actomyosin-driven collagen remodeling, thereby reducing DC-T cell encounters and weakening T cell priming, activation, proliferation, and tumor killing. Blocking DC migration in fast-relaxing gels recapitulated key aspects of the impaired T cell priming seen in elastic matrices. Prolonged confinement in elastic extracellular matrix induced a mechanomemory state, locking DCs into reduced motility even after transfer to viscoelastic environments, corresponding to altered chromatin accessibility. Finally, studies with patient-derived ependymoma samples confirmed these findings, identifying viscoelasticity as a barrier to antitumor immunity with implications for therapeutic intervention.
Open AccessMatrix viscoelasticity regulates dendritic cell migration and immune priming
The tumor microenvironment shapes immune surveillance through its mechanical properties, yet the role of matrix viscoelasticity remains unclear. Here, we used a collagen system with tunable viscoelasticity to define how matrix relaxation directs dendritic cell (DC) behavior. Elastic matrices impaired DC migration by limiting actomyosin-driven collagen remodeling, thereby reducing DC-T cell encounters and weakening T cell priming, activation, proliferation, and tumor killing. Blocking DC migration in fast-relaxing gels recapitulated key aspects of the impaired T cell priming seen in elastic matrices. Prolonged confinement in elastic extracellular matrix induced a mechanomemory state, locking DCs into reduced motility even after transfer to viscoelastic environments, corresponding to altered chromatin accessibility. Finally, studies with patient-derived ependymoma samples confirmed these findings, identifying viscoelasticity as a barrier to antitumor immunity with implications for therapeutic intervention.
- Open Access
- 21 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31797
Prediction of B/T Subtype and ETV6–RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia by Deep Learning Analysis of Giemsa‐Stained Whole Slide Images of Bone Marrow Aspirates
Background: Accurate determination of B/T‐cell lineage and the presence of the ETV6–RUNX1 translocation is critical for diagnosing acute lymphoblastic leukemia (ALL), as these factors influence treatment decisions and outcomes. However, these diagnostic processes often rely on advanced tools unavailable in low‐resource settings, creating a need for alternative solutions.Procedure: We developed a deep learning pipeline to analyze Giemsa‐stained bone marrow (BM) aspirate smears. The models were trained to distinguish between ALL, acute myeloid leukemia (AML), and non‐leukemic BM samples, predict B‐ and T‐cell lineage in ALL, and detect the presence of the ETV6–RUNX1 translocation. The performance was evaluated using cross‐validation (CV) and an external validation cohort.Results: The models achieved a statistically significant area under the curve (AUC) of 0.99 in distinguishing ALL from AML and control samples. In cross‐validation (CV), the models achieved a cross‐validation AUC of 0.74 for predicting B/T subtypes. For predicting ETV6–RUNX1 translocation, the models achieved an AUC of 0.80. External cohort validation confirmed significant AUCs of 0.72 for B/T subtype classification and 0.69 for ETV6–RUNX1 translocation prediction.Conclusions: Convolutional neural networks (CNNs) demonstrate potential as a diagnostic tool for pediatric ALL, enabling the identification of B/T lineage and ETV6–RUNX1 translocation from Giemsa‐stained smears. These results pave the way for future utilization of CNNs as a diagnostic modality for pediatric leukemia in low‐resource settings, where access to advanced diagnostic techniques is limited.
- 21 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31797
Open AccessPrediction of B/T Subtype and ETV6–RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia by Deep Learning Analysis of Giemsa‐Stained Whole Slide Images of Bone Marrow Aspirates
Background: Accurate determination of B/T‐cell lineage and the presence of the ETV6–RUNX1 translocation is critical for diagnosing acute lymphoblastic leukemia (ALL), as these factors influence treatment decisions and outcomes. However, these diagnostic processes often rely on advanced tools unavailable in low‐resource settings, creating a need for alternative solutions.Procedure: We developed a deep learning pipeline to analyze Giemsa‐stained bone marrow (BM) aspirate smears. The models were trained to distinguish between ALL, acute myeloid leukemia (AML), and non‐leukemic BM samples, predict B‐ and T‐cell lineage in ALL, and detect the presence of the ETV6–RUNX1 translocation. The performance was evaluated using cross‐validation (CV) and an external validation cohort.Results: The models achieved a statistically significant area under the curve (AUC) of 0.99 in distinguishing ALL from AML and control samples. In cross‐validation (CV), the models achieved a cross‐validation AUC of 0.74 for predicting B/T subtypes. For predicting ETV6–RUNX1 translocation, the models achieved an AUC of 0.80. External cohort validation confirmed significant AUCs of 0.72 for B/T subtype classification and 0.69 for ETV6–RUNX1 translocation prediction.Conclusions: Convolutional neural networks (CNNs) demonstrate potential as a diagnostic tool for pediatric ALL, enabling the identification of B/T lineage and ETV6–RUNX1 translocation from Giemsa‐stained smears. These results pave the way for future utilization of CNNs as a diagnostic modality for pediatric leukemia in low‐resource settings, where access to advanced diagnostic techniques is limited.
- Open Access
- 20 December 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-16
Clinical utility of receptor status prediction in breast cancer and misdiagnosis identification using deep learning on hematoxylin and eosin-stained slides
Background Molecular profiling of estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (also known as Her2) is essential for breast cancer diagnosis and treatment planning. Nevertheless, current methods rely on the qualitative interpretation of immunohistochemistry and fluorescence in situ hybridization (FISH), which can be costly, time-consuming, and inconsistent. Here we explore the clinical utility of predicting receptor status from digitized hematoxylin and eosin-stained (H&E) slides using machine learning trained and evaluated on a multi-institutional dataset. Methods We developed a deep learning system to predict ER, PR, and ERBB2 statuses from digitized H&E slides and evaluated its utility in three clinical applications: identifying hormone receptor-positive patients, serving as a second-read tool for quality assurance, and addressing intratumor heterogeneity. For development and validation, we collected 19,845 slides from 7,950 patients across six independent cohorts representative of diverse clinical settings. Results Here we show that the system identifies 30.5% of patients as hormone receptor-positive, achieving a specificity of 0.9982 and a positive predictive value of 0.9992, demonstrating its ability to determine eligibility for hormone therapy without immunohistochemistry. By restaining and reassessing samples flagged as potential false negatives, we discover 31 cases of misdiagnosed ER, PR, and ERBB2 statuses. Conclusions These findings demonstrate the utility of the system in diverse clinical settings and its potential to improve breast cancer diagnosis. Given the substantial focus of current guidelines on reducing false negative diagnoses, this study supports the integration of H&E-based machine learning tools into workflows for quality assurance.
- 20 December 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-16
Open AccessClinical utility of receptor status prediction in breast cancer and misdiagnosis identification using deep learning on hematoxylin and eosin-stained slides
Background Molecular profiling of estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (also known as Her2) is essential for breast cancer diagnosis and treatment planning. Nevertheless, current methods rely on the qualitative interpretation of immunohistochemistry and fluorescence in situ hybridization (FISH), which can be costly, time-consuming, and inconsistent. Here we explore the clinical utility of predicting receptor status from digitized hematoxylin and eosin-stained (H&E) slides using machine learning trained and evaluated on a multi-institutional dataset. Methods We developed a deep learning system to predict ER, PR, and ERBB2 statuses from digitized H&E slides and evaluated its utility in three clinical applications: identifying hormone receptor-positive patients, serving as a second-read tool for quality assurance, and addressing intratumor heterogeneity. For development and validation, we collected 19,845 slides from 7,950 patients across six independent cohorts representative of diverse clinical settings. Results Here we show that the system identifies 30.5% of patients as hormone receptor-positive, achieving a specificity of 0.9982 and a positive predictive value of 0.9992, demonstrating its ability to determine eligibility for hormone therapy without immunohistochemistry. By restaining and reassessing samples flagged as potential false negatives, we discover 31 cases of misdiagnosed ER, PR, and ERBB2 statuses. Conclusions These findings demonstrate the utility of the system in diverse clinical settings and its potential to improve breast cancer diagnosis. Given the substantial focus of current guidelines on reducing false negative diagnoses, this study supports the integration of H&E-based machine learning tools into workflows for quality assurance.
- 3 June 2024
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (2) , 268-278
Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells
The efficacy of adoptive T-cell therapies based on chimaeric antigen receptors (CARs) is limited by the poor proliferation and persistence of the engineered T cells. Here we show that a subcutaneously injected biodegradable scaffold that facilitates the infiltration and egress of specific T-cell subpopulations, which forms a microenvironment mimicking features of physiological T-cell activation, enhances the antitumour activity of pre-administered CAR-T cells. CAR-T-cell expansion, differentiation and cytotoxicity were driven by the scaffold’s incorporation of co-stimulatory bound ligands and soluble molecules, and depended on the types of co-stimulatory molecules and the context in which they were presented. In mice with aggressive lymphoma, a single, local injection of the scaffold following non-curative CAR-T-cell dosing led to more persistent memory-like T cells and extended animal survival. Injectable biomaterials with optimized ligand presentation may boost the therapeutic performance of CAR-T-cell therapies.
- 3 June 2024
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (2) , 268-278
Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells
The efficacy of adoptive T-cell therapies based on chimaeric antigen receptors (CARs) is limited by the poor proliferation and persistence of the engineered T cells. Here we show that a subcutaneously injected biodegradable scaffold that facilitates the infiltration and egress of specific T-cell subpopulations, which forms a microenvironment mimicking features of physiological T-cell activation, enhances the antitumour activity of pre-administered CAR-T cells. CAR-T-cell expansion, differentiation and cytotoxicity were driven by the scaffold’s incorporation of co-stimulatory bound ligands and soluble molecules, and depended on the types of co-stimulatory molecules and the context in which they were presented. In mice with aggressive lymphoma, a single, local injection of the scaffold following non-curative CAR-T-cell dosing led to more persistent memory-like T cells and extended animal survival. Injectable biomaterials with optimized ligand presentation may boost the therapeutic performance of CAR-T-cell therapies.
- Open Access
- 1 December 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (12) , 2350-2356
Neutrophil Elastase Activity as a Surrogate Marker for Neutrophil Extracellular Trap Formation following Hematopoietic Stem Cell Transplantation
- 1 December 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (12) , 2350-2356
Open AccessNeutrophil Elastase Activity as a Surrogate Marker for Neutrophil Extracellular Trap Formation following Hematopoietic Stem Cell Transplantation
- 26 September 2017
- Published by AIP Publishing in Physics of Plasmas
- Vol. 24 (10)
Electrical model of cold atmospheric plasma gun
We present an analytical model of cold atmospheric plasma formed by a dielectric barrier discharge (DBD), which is based on the lumped and distributed elements of an equivalent electric circuit of this plasma. This model is applicable for a wide range of frequencies and amplitudes of the applied voltage pulses, no matter whether or not the generated plasma plume interacts with a target. The model allows quantitative estimation of the plasma plume length and the energy delivered to the plasma. Also, the results of this model can be used for the design of DBD guns which efficiently generate cold atmospheric plasma. A comparison of the results of the model with those obtained in experiments shows a fairly good agreement.
- 26 September 2017
- Published by AIP Publishing in Physics of Plasmas
- Vol. 24 (10)
Electrical model of cold atmospheric plasma gun
We present an analytical model of cold atmospheric plasma formed by a dielectric barrier discharge (DBD), which is based on the lumped and distributed elements of an equivalent electric circuit of this plasma. This model is applicable for a wide range of frequencies and amplitudes of the applied voltage pulses, no matter whether or not the generated plasma plume interacts with a target. The model allows quantitative estimation of the plasma plume length and the energy delivered to the plasma. Also, the results of this model can be used for the design of DBD guns which efficiently generate cold atmospheric plasma. A comparison of the results of the model with those obtained in experiments shows a fairly good agreement.